|
|
|
| Expression of Serum miR-9-5p and miR-576-5p in Patients with Endometrial Cancer and the Clinical Significances |
| DU Lin, DU Xiaoyan |
| The First Hospital of Harbin, Heilongjiang Harbin 150026, China |
|
|
|
|
Abstract Objective: To investigate the relationship between expression of serum miR-9-5p and miR-576-5p with clinicopathological features and prognosis in patients with endometrial cancer. Methods: A total of 98 patients with endometrial cancer admitted to the department of obstetrics and gynecology of our hospital from January 2018 to January 2021 (endometrial cancer group) and 72 healthy women who underwent physical examination in the department of obstetrics and gynecology during the same period (control group) were recruited. Peripheral venous blood was collected, and the expressions of miR-9-5p and miR-576-5p in serum were detected by real-time fluorescent quantitative polymerase chain reaction (RT-PCR), and the differences in expressions of serum miR-9-5p and miR-576-5p of patients with different pathological characteristics were compared. The 3-year overall survival (OS) was measured by regular follow-up after discharge. Results: The expression of miR-9-5p in endometrial carcinoma group was significantly lower than that in control group (0.86±0.21 vs 2.55±0.93, t=-17.412, P<0.05), and the expression of miR-576-5p was significantly higher than that of control group (3.42±1.16 vs 1.57±0.45, t=12.833, P<0.05). Significantly lower serum miR-9-5p expression and higher miR-576-5p were detected in endometrial cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) stages Ⅲ- Ⅳ, low differentiation, deep muscle infiltration, lymph node metastasis, and distant metastasis compared to those with FIGO stages Ⅰ~Ⅱ, medium-highly differentiation, shallow muscle infiltration, no lymph node metastasis, and no distant metastasis (all P<0.05). After 3 years of follow-up, 2 cases were lost to follow-up, 36 died and 60 survived. The 3-year OS rate of endometrial cancer patients with low expression of miR-9-5p was significantly lower than that of endometrial cancer patients with high expression of miR-9-5p (P<0.05); the 3-year OS rate of endometrial cancer patients with high expression of miR-576-5p was significantly lower than that of endometrial cancer patients with low expression of miR-576-5p (P<0.05). Lymph node metastasis, distant metastasis and high miR-576-5p were risk factors for death of endometrial cancer (HR [95%CI]: 1.921 [1.179~3.130], 2.050 [1.121~3.750], 1.683 [1.162~2.439], P＜0.05), and high expression of miR-9-5p was protective factor (HR [95%CI]: 0.670 [0.497~0.905], P＜0.05). Conclusion: The down-regulated miR-9-5p and up-regulated miR-576-5p are found in patients with endometrial carcinoma, which are related to malignant pathological features and poor prognosis.
|
|
|
|
|
|
[1] Crosbie EJ,Kitson SJ,Mcalpine JN,et al.Endometrial cancer[J].Lancet,2022,399(10333):1412-1428.
[2] Shetty A,Venkatesh T,Kabbekodu SP,et al.LncRNA-miRNA-mRNA regulatory axes in endometrial cancer:a comprehensive overview[J].Arch Gynecol Obstet,2022,306(5):1431-1447.
[3] Wei YQ,Jiao XL,Zhang SY,et al.MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5[J].Eur Rev Med Pharmacol Sci,2019,23(17):7314-7326.
[4] Jin L,Li X,Zhao Y,et al.miR-576-5p facilitates aggressive cell behaviors in colon adenocarcinoma via targeting NEGR1[J].Crit Rev Eukaryot Gene Expr,2022,32(7):25-33.
[5] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(第4版)[J].中国实用妇科与产科杂志,2018,34(8):880-886.
[6] Ye Z,Jiang Y,Wu J.A novel necroptosis-associated miRNA signature predicting prognosis of endometrial cancer and correlated with immune infiltration[J].Taiwan Obstet Gynecol,2023,62(2):291-298.
[7] Wang J,Wang B,Ren H,et al.miR-9-5p inhibits pancreatic cancer cell proliferation,invasion and glutamine metabolism by targeting GOT1[J].Biochem Biophys Res Commun,2019,509(1):241-248.
[8] 黄振宇,杨剑波,凌雪君,等.LncRNA Hulc和miR-9-5p在乳腺癌中的表达水平及临床意义[J].中国肿瘤外科杂志,2020,12(4):360-365.
[9] Luo J,Liu L,Shen J,et al.miR-576-5p promotes epithelial-to-mesenchymal transition in colorectal cancer by targeting the Wnt5a-mediated Wnt/β-catenin signaling pathway[J].Mol Med Rep,2021,23(2):94.
[10] Wu Y,Zhou J,Li Y,et al.Hsa_circ_0001445 works as a cancer suppressor via miR-576-5p/SFRP1 axis regulation in ovarian cancer[J].Cancer Med,2023,12(5):5736-5750.
[11] Chen C,Zhang Q,Kong B.miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4[J].Clin Transl Oncol,2023,25(3):706-720. |
|
|
|
2025, Vol. 31 
